Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors
DNA polymerase theta (Polθ) has recently emerged as a new attractive synthetic lethal target involved in DNA damage repair. Inactivating Polθ alone or in combination with PARP inhibitors has demonstrated substantial therapeutic potential against tumors with homologous recombination (HR) defects such as alternation of BRCA genes. Herein, we report the design and proof of concept of a highly potent dual Polθ/PARP inhibitor 25d, which exhibited low nanomolar inhibitory activities against both Polθ and PARP1. Compared to combination treatment, 25d demonstrated superior antitumor efficacy in both MDA-MB-436 cells and xenografts by inducing more DNA damage and apoptosis. Importantly, 25d retained sensitivity in PARP inhibitor-resistant MDA-MB-436 cells with 53BP1 defect. Altogether, these findings illustrate the potential advantages of 25d, a first-in-class dual Polθ/PARP inhibitor, over monotherapy in treating HR-deficient tumors, including those with acquired PARP inhibitor resistance.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
---|---|
Enthalten in: |
Journal of medicinal chemistry - 67(2024), 5 vom: 14. März, Seite 3606-3625 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ma, Luyu [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antineoplastic Agents |
---|
Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1021/acs.jmedchem.3c02096 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368658163 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368658163 | ||
003 | DE-627 | ||
005 | 20240315233341.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240220s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1021/acs.jmedchem.3c02096 |2 doi | |
028 | 5 | 2 | |a pubmed24n1330.xml |
035 | |a (DE-627)NLM368658163 | ||
035 | |a (NLM)38375763 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ma, Luyu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.03.2024 | ||
500 | |a Date Revised 15.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a DNA polymerase theta (Polθ) has recently emerged as a new attractive synthetic lethal target involved in DNA damage repair. Inactivating Polθ alone or in combination with PARP inhibitors has demonstrated substantial therapeutic potential against tumors with homologous recombination (HR) defects such as alternation of BRCA genes. Herein, we report the design and proof of concept of a highly potent dual Polθ/PARP inhibitor 25d, which exhibited low nanomolar inhibitory activities against both Polθ and PARP1. Compared to combination treatment, 25d demonstrated superior antitumor efficacy in both MDA-MB-436 cells and xenografts by inducing more DNA damage and apoptosis. Importantly, 25d retained sensitivity in PARP inhibitor-resistant MDA-MB-436 cells with 53BP1 defect. Altogether, these findings illustrate the potential advantages of 25d, a first-in-class dual Polθ/PARP inhibitor, over monotherapy in treating HR-deficient tumors, including those with acquired PARP inhibitor resistance | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
700 | 1 | |a Chen, Wei |e verfasserin |4 aut | |
700 | 1 | |a Yang, Ming |e verfasserin |4 aut | |
700 | 1 | |a Ha, Si |e verfasserin |4 aut | |
700 | 1 | |a Xiong, Shuangshuang |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Jiacheng |e verfasserin |4 aut | |
700 | 1 | |a Xiang, Hua |e verfasserin |4 aut | |
700 | 1 | |a Luo, Guoshun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 67(2024), 5 vom: 14. März, Seite 3606-3625 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
773 | 1 | 8 | |g volume:67 |g year:2024 |g number:5 |g day:14 |g month:03 |g pages:3606-3625 |
856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.3c02096 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 67 |j 2024 |e 5 |b 14 |c 03 |h 3606-3625 |